Your browser is no longer supported. Please, upgrade your browser.
Settings
SBBP Strongbridge Biopharma plc daily Stock Chart
SBBP [NASD]
Strongbridge Biopharma plc
Index- P/E- EPS (ttm)-0.97 Insider Own1.20% Shs Outstand54.30M Perf Week-5.83%
Market Cap135.49M Forward P/E- EPS next Y-0.43 Insider Trans192.11% Shs Float35.84M Perf Month-2.78%
Income-52.70M PEG- EPS next Q-0.13 Inst Own58.10% Short Float2.44% Perf Quarter-41.67%
Sales25.70M P/S5.27 EPS this Y-242.50% Inst Trans4.30% Short Ratio1.55 Perf Half Y-11.76%
Book/sh0.88 P/B2.39 EPS next Y19.70% ROA-48.00% Target Price- Perf Year5.53%
Cash/sh0.93 P/C2.26 EPS next 5Y20.00% ROE-80.90% 52W Range1.43 - 4.63 Perf YTD0.48%
Dividend- P/FCF- EPS past 5Y-16.70% ROI-95.40% 52W High-54.64% Beta1.71
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin87.00% 52W Low46.85% ATR0.13
Employees71 Current Ratio3.40 Sales Q/Q27.90% Oper. Margin- RSI (14)33.89 Volatility5.33% 5.05%
OptionableYes Debt/Eq0.15 EPS Q/Q-108.90% Profit Margin- Rel Volume0.59 Prev Close2.07
ShortableYes LT Debt/Eq0.14 EarningsOct 29 AMC Payout- Avg Volume564.92K Price2.10
Recom1.40 SMA20-2.51% SMA50-24.31% SMA200-28.82% Volume332,483 Change1.45%
Mar-03-20Initiated Craig Hallum Buy $7.50
Sep-25-19Initiated Evercore ISI Outperform
Sep-24-19Initiated Jefferies Buy $8
Dec-18-18Initiated Laidlaw Buy $11
Dec-06-17Initiated Cantor Fitzgerald Buy $14
Jan-25-17Reiterated H.C. Wainwright Buy $15 → $18
Apr-25-16Initiated H.C. Wainwright Buy $15
Nov-10-15Initiated Stifel Buy $21
Nov-10-15Initiated JMP Securities Mkt Outperform
Oct-22-20 07:30AM  
Sep-30-20 06:05PM  
Sep-28-20 10:30PM  
Sep-27-20 01:08AM  
Sep-23-20 10:30PM  
Sep-21-20 09:30PM  
Sep-19-20 05:14PM  
Sep-17-20 08:00AM  
Sep-16-20 11:29PM  
04:35PM  
01:05PM  
Sep-14-20 08:32PM  
11:00AM  
Sep-08-20 08:00AM  
06:30AM  
Aug-28-20 01:37PM  
Aug-04-20 09:05AM  
07:30AM  
Jul-28-20 07:30AM  
Jul-22-20 12:32PM  
Jul-07-20 07:30AM  
Jul-05-20 10:26PM  
Jul-01-20 07:30AM  
Jun-01-20 07:30AM  
May-27-20 11:34AM  
May-20-20 07:30AM  
May-18-20 10:04AM  
07:30AM  
May-15-20 06:33AM  
May-11-20 07:30AM  
May-06-20 09:35AM  
08:25AM  
07:30AM  
Apr-29-20 12:34PM  
Apr-20-20 07:30AM  
Mar-07-20 12:26AM  
Feb-27-20 08:35AM  
07:30AM  
Feb-25-20 08:55AM  
07:30AM  
06:30AM  
Feb-19-20 07:30AM  
Jan-30-20 04:30PM  
Jan-09-20 07:30AM  
Dec-16-19 07:35AM  
Nov-18-19 01:03PM  
07:30AM  
Nov-17-19 09:25AM  
Nov-12-19 07:30AM  
Nov-07-19 09:05AM  
07:30AM  
Nov-06-19 08:21AM  
Nov-05-19 03:32PM  
06:30AM  
Oct-31-19 10:33AM  
Oct-29-19 07:30AM  
Oct-23-19 10:33AM  
Oct-17-19 07:30AM  
Sep-25-19 09:04AM  
Sep-19-19 07:30AM  
Sep-03-19 07:30AM  
Aug-21-19 10:12PM  
Aug-13-19 08:45AM  
Jul-31-19 09:15AM  
07:30AM  
Jul-24-19 07:30AM  
Jul-19-19 07:30AM  
Jul-11-19 06:40AM  
Jul-01-19 07:30AM  
Jun-23-19 04:11PM  
Jun-12-19 07:30AM  
Jun-04-19 07:30AM  
May-30-19 07:30AM  
May-09-19 04:05PM  
May-06-19 05:24PM  
May-04-19 11:14PM  
May-02-19 12:23AM  
May-01-19 01:16PM  
11:12AM  
07:30AM  
Apr-26-19 09:43AM  
08:02AM  
Apr-25-19 04:01PM  
Apr-24-19 07:30AM  
Apr-18-19 10:13AM  
Apr-15-19 07:30AM  
Mar-25-19 07:30AM  
Mar-11-19 12:36PM  
07:30AM  
Mar-08-19 07:30AM  
Mar-04-19 08:58AM  
07:30AM  
Feb-27-19 07:30AM  
Feb-26-19 10:44AM  
07:30AM  
Feb-22-19 07:30AM  
Feb-19-19 07:30AM  
Jan-31-19 11:21AM  
Jan-23-19 09:19AM  
Dec-19-18 11:15AM  
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILL DAVID NDirectorSep 24Buy2.138,00017,04074,896Sep 28 07:48 AM
CDK ASSOCIATES, L.L.C.10% OwnerSep 18Buy2.206,00013,2008,060,682Sep 21 09:48 PM
CDK ASSOCIATES, L.L.C.10% OwnerSep 17Buy2.251,473,3773,315,0988,054,682Sep 21 09:48 PM
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.44 Insider Own1.20% Shs Outstand178.33M Perf Week2.33%
Market Cap3.07B Forward P/E- EPS next Y-2.48 Insider Trans-5.29% Shs Float177.51M Perf Month-2.72%
Income-430.90M PEG- EPS next Q-0.74 Inst Own99.20% Short Float14.35% Perf Quarter-25.84%
Sales162.50M P/S18.91 EPS this Y-166.60% Inst Trans0.35% Short Ratio26.12 Perf Half Y-12.69%
Book/sh7.04 P/B2.49 EPS next Y12.70% ROA-22.80% Target Price- Perf Year6.50%
Cash/sh5.93 P/C2.96 EPS next 5Y-7.30% ROE-31.60% 52W Range13.63 - 28.60 Perf YTD-18.74%
Dividend- P/FCF- EPS past 5Y-42.70% ROI-26.60% 52W High-38.67% Beta1.86
Dividend %- Quick Ratio9.20 Sales past 5Y-10.60% Gross Margin87.40% 52W Low28.69% ATR0.73
Employees723 Current Ratio9.30 Sales Q/Q109.40% Oper. Margin- RSI (14)48.53 Volatility4.07% 3.95%
OptionableYes Debt/Eq0.00 EPS Q/Q28.80% Profit Margin- Rel Volume0.69 Prev Close17.18
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume975.15K Price17.54
Recom2.30 SMA202.08% SMA50-5.06% SMA200-14.46% Volume677,511 Change2.10%
Sep-14-20Initiated JP Morgan Neutral $26
Jun-10-20Downgrade CFRA Hold → Sell
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Mar-30-20Upgrade Goldman Sell → Neutral $18 → $20
Mar-04-20Initiated Barclays Overweight $30
Feb-03-20Upgrade Mizuho Neutral → Buy $21 → $35
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Oct-05-20 03:27PM  
Sep-28-20 05:24PM  
Sep-24-20 06:47PM  
Sep-05-20 11:32AM  
Aug-12-20 09:42AM  
08:00AM  
Aug-07-20 11:35AM  
Aug-06-20 07:00PM  
04:15PM  
Aug-05-20 11:15AM  
Jul-30-20 12:33PM  
Jul-28-20 06:00PM  
Jun-23-20 09:46PM  
Jun-14-20 09:25PM  
Jun-06-20 11:31AM  
Jun-04-20 05:00PM  
May-29-20 05:00PM  
May-26-20 11:11AM  
May-22-20 08:30AM  
May-18-20 08:05AM  
May-17-20 07:13PM  
May-12-20 06:27AM  
May-08-20 10:29AM  
03:57AM  
03:31AM  
May-07-20 05:55PM  
04:15PM  
Apr-30-20 12:33PM  
Apr-28-20 05:00PM  
Apr-09-20 06:08PM  
Apr-06-20 06:24AM  
Mar-29-20 10:51PM  
Mar-28-20 11:30AM  
Mar-11-20 09:19PM  
Mar-01-20 09:15AM  
Feb-28-20 06:30PM  
08:15AM  
04:39AM  
Feb-27-20 05:35PM  
04:15PM  
Feb-20-20 12:31PM  
Feb-18-20 05:00PM  
Feb-17-20 10:27AM  
Feb-10-20 02:56PM  
09:28AM  
Feb-06-20 05:50PM  
Feb-03-20 09:12AM  
08:00AM  
Jan-29-20 03:46PM  
Jan-27-20 09:08AM  
Jan-24-20 07:02PM  
Jan-23-20 11:43AM  
Jan-21-20 05:53PM  
Jan-16-20 01:37PM  
Jan-15-20 04:08PM  
10:27AM  
10:23AM  
09:17AM  
08:22AM  
07:30AM  
04:44AM  
Jan-14-20 10:47PM  
06:27PM  
10:49AM  
05:00AM  
Jan-13-20 09:14AM  
Jan-10-20 04:08PM  
02:32PM  
01:34PM  
08:01AM  
06:59AM  
Jan-07-20 09:00AM  
Dec-24-19 01:09PM  
10:10AM  
Dec-19-19 12:21PM  
08:59AM  
Dec-17-19 09:00AM  
Dec-10-19 07:49PM  
05:00AM  
Dec-09-19 10:05AM  
Dec-06-19 11:31AM  
Dec-03-19 09:00AM  
Nov-13-19 05:30PM  
Nov-12-19 11:11PM  
09:33AM  
Nov-11-19 04:25PM  
08:55AM  
Nov-10-19 11:00AM  
Nov-09-19 05:30PM  
Nov-07-19 11:13AM  
Nov-06-19 06:15PM  
04:03PM  
Nov-03-19 10:51AM  
Nov-01-19 09:00AM  
Oct-30-19 05:00PM  
10:34AM  
Oct-28-19 07:46PM  
Oct-25-19 06:00AM  
Oct-23-19 03:26PM  
Oct-18-19 03:00PM  
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ajer Jeffrey RobertDirectorSep 28Sale17.253,25056,06325,975Sep 30 07:03 PM
CHESS ROBERTDirectorSep 25Sale17.755,50097,625280,573Sep 25 08:16 PM
Ajer Jeffrey RobertDirectorSep 21Sale19.742,25044,41520,125Sep 21 08:58 PM
Labrucherie Gil MSVP, COO & CFOSep 17Sale19.962,00039,920235,249Sep 21 08:59 PM
CHESS ROBERTDirectorSep 08Option Exercise9.248,00073,920284,973Sep 10 08:19 PM
CHESS ROBERTDirectorSep 08Sale18.538,000148,240276,973Sep 10 08:19 PM
WHITFIELD ROY ADirectorSep 04Option Exercise9.2430,000277,200228,250Sep 08 06:18 PM
Labrucherie Gil MSVP, COO & CFOAug 18Sale19.682,00039,360237,249Aug 19 06:37 PM
Zalevsky JonathanChief R&D OfficerAug 17Sale19.6726,200515,354296,315Aug 19 06:41 PM
Wilson Mark AndrewSVP & General CounselAug 17Sale19.671,52930,07551,389Aug 19 06:40 PM
ROBIN HOWARD WPresident & CEOAug 17Sale19.6711,885233,778364,018Aug 19 06:38 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 17Sale19.671,36726,889171,733Aug 19 06:39 PM
Labrucherie Gil MSVP, COO & CFOAug 17Sale19.676,245122,839239,249Aug 19 06:37 PM
GREER R SCOTTDirectorJul 09Option Exercise9.2440,000369,600191,583Jul 10 07:06 PM
GREER R SCOTTDirectorJul 09Sale25.0015,009375,225176,574Jul 10 07:06 PM
CHESS ROBERTDirectorJul 08Option Exercise9.248,00073,920284,973Jul 10 07:05 PM
CHESS ROBERTDirectorJul 08Sale24.588,000196,640276,973Jul 10 07:05 PM
Labrucherie Gil MSVP, COO & CFOMay 19Sale22.622,00045,240245,494May 20 06:29 PM
Zalevsky JonathanChief R&D OfficerMay 18Sale22.514,558102,601322,515May 20 06:33 PM
Wilson Mark AndrewSVP & General CounselMay 18Sale22.511,52934,41852,418May 20 06:32 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 18Sale22.511,36730,771172,719May 20 06:31 PM
Labrucherie Gil MSVP, COO & CFOMay 18Sale22.515,727128,915247,494May 20 06:29 PM
ROBIN HOWARD WPresident & CEOMay 18Sale22.518,968201,870375,903May 20 06:30 PM
CHESS ROBERTDirectorApr 15Sale18.388,000147,010276,973Apr 17 06:03 PM
CHESS ROBERTDirectorMar 11Sale16.798,000134,316276,973Mar 13 06:04 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 18Sale22.351,39431,156174,086Feb 20 06:39 PM
Zalevsky JonathanChief R&D OfficerFeb 18Sale22.354,774106,699327,073Feb 20 06:39 PM
Labrucherie Gil MSVP, COO & CFOFeb 18Sale22.355,938132,714253,221Feb 20 06:37 PM
ROBIN HOWARD WPresident & CEOFeb 18Sale22.358,448188,813384,871Feb 20 06:38 PM
CHESS ROBERTDirectorFeb 12Sale23.508,000188,000276,973Feb 14 07:00 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Option Exercise7.2137,500270,375212,980Feb 07 07:31 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Sale22.7837,500854,250175,480Feb 07 07:31 PM
WHITFIELD ROY ADirectorDec 18Option Exercise9.2410,00092,400198,250Dec 20 06:31 PM
Zalevsky JonathanChief R&D OfficerNov 18Sale17.973,96071,161291,697Nov 20 07:07 PM
ROBIN HOWARD WPresident & CEONov 18Sale17.9713,556243,601299,219Nov 20 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 18Sale17.972,71348,753160,441Nov 20 07:06 PM
Labrucherie Gil MSVP, COO & CFONov 18Sale17.978,863159,268219,009Nov 20 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 13Option Exercise7.2125,000180,250252,872Nov 15 06:09 PM
Labrucherie Gil MSVP, COO & CFONov 13Sale19.7925,000494,750227,872Nov 15 06:09 PM
PCRX Pacira BioSciences, Inc. daily Stock Chart
PCRX [NASD]
Pacira BioSciences, Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own1.30% Shs Outstand42.22M Perf Week-0.93%
Market Cap2.32B Forward P/E14.29 EPS next Y3.88 Insider Trans-53.16% Shs Float39.50M Perf Month-2.77%
Income-10.10M PEG- EPS next Q0.61 Inst Own- Short Float14.35% Perf Quarter3.98%
Sales408.30M P/S5.69 EPS this Y22.80% Inst Trans0.15% Short Ratio10.92 Perf Half Y34.57%
Book/sh9.19 P/B6.04 EPS next Y88.72% ROA-1.20% Target Price66.08 Perf Year42.30%
Cash/sh7.81 P/C7.10 EPS next 5Y31.00% ROE-2.80% 52W Range27.46 - 64.44 Perf YTD22.45%
Dividend- P/FCF177.21 EPS past 5Y7.30% ROI1.50% 52W High-13.92% Beta1.11
Dividend %- Quick Ratio5.50 Sales past 5Y16.30% Gross Margin74.00% 52W Low102.00% ATR2.26
Employees606 Current Ratio6.50 Sales Q/Q-26.40% Oper. Margin3.40% RSI (14)41.23 Volatility4.16% 3.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-367.10% Profit Margin-2.50% Rel Volume0.48 Prev Close54.31
ShortableYes LT Debt/Eq0.81 EarningsOct 29 BMO Payout- Avg Volume519.17K Price55.47
Recom2.10 SMA20-3.84% SMA50-6.61% SMA20015.28% Volume248,092 Change2.14%
Sep-21-20Upgrade Northland Capital Market Perform → Outperform $58 → $67
Jul-06-20Reiterated Needham Buy $52 → $64
May-27-20Initiated Guggenheim Neutral
Apr-07-20Initiated Northland Capital Outperform $50
Mar-20-20Upgrade SVB Leerink Mkt Perform → Outperform $44
Feb-24-20Reiterated H.C. Wainwright Buy $60 → $63
Jan-24-20Initiated SunTrust Buy
Jan-23-20Initiated SunTrust Buy
Nov-06-19Initiated BTIG Research Buy $56
Jun-11-19Initiated Barclays Overweight $52
May-06-19Upgrade Mizuho Underperform → Neutral $29 → $38
May-02-19Upgrade Stifel Sell → Hold $45
Feb-01-19Downgrade Mizuho Neutral → Underperform
Aug-06-18Downgrade BofA/Merrill Buy → Neutral
Apr-09-18Reiterated H.C. Wainwright Buy $45 → $48
Mar-21-18Reiterated Mizuho Neutral $44 → $31
Feb-16-18Downgrade Needham Buy → Hold
Jan-19-18Initiated Seaport Global Securities Buy $50
Jan-04-18Reiterated Canaccord Genuity Buy $42 → $46
Jan-03-18Initiated Leerink Partners Mkt Perform $46
Oct-22-20 12:33PM  
Oct-21-20 07:30AM  
06:25AM  
Oct-20-20 07:30AM  
Oct-19-20 11:30AM  
Oct-07-20 08:00AM  
Sep-21-20 11:56AM  
Sep-18-20 08:07AM  
Sep-16-20 02:55PM  
Sep-15-20 07:30AM  
Sep-11-20 07:30AM  
Sep-09-20 08:00AM  
Sep-05-20 11:31AM  
Aug-06-20 08:00AM  
Aug-05-20 04:05PM  
07:30AM  
Aug-04-20 07:30AM  
Jul-30-20 07:30AM  
Jul-28-20 05:03PM  
Jul-12-20 12:43PM  
Jul-07-20 07:51PM  
Jul-06-20 04:02PM  
04:01PM  
Jul-02-20 07:30AM  
Jun-29-20 09:00AM  
Jun-16-20 07:30AM  
Jun-10-20 04:36PM  
May-27-20 07:30AM  
May-13-20 07:30AM  
May-07-20 08:00AM  
May-04-20 07:30AM  
Apr-30-20 07:30AM  
Apr-23-20 08:59AM  
Apr-07-20 05:00PM  
Apr-06-20 08:00AM  
Mar-21-20 11:30AM  
Mar-17-20 09:53AM  
Mar-13-20 12:45PM  
11:40AM  
Mar-10-20 10:24AM  
Mar-09-20 07:30AM  
Mar-05-20 07:44AM  
Mar-04-20 09:22AM  
Feb-27-20 12:32AM  
Feb-26-20 12:45PM  
11:40AM  
Feb-23-20 09:46AM  
Feb-21-20 10:22AM  
09:45AM  
Feb-20-20 08:00AM  
Feb-19-20 09:21AM  
Feb-13-20 07:30AM  
Feb-12-20 09:45AM  
Feb-11-20 06:39AM  
Feb-07-20 06:52AM  
Feb-06-20 08:36AM  
08:10AM  
Feb-05-20 08:37AM  
Feb-03-20 08:53AM  
Jan-22-20 08:53AM  
Jan-21-20 09:06AM  
07:30AM  
Jan-13-20 11:40AM  
Jan-09-20 07:30AM  
Jan-08-20 11:16AM  
07:30AM  
Jan-07-20 02:08PM  
10:21AM  
07:30AM  
Dec-27-19 11:40AM  
Dec-26-19 11:52AM  
Dec-18-19 09:23AM  
Dec-17-19 07:30AM  
Dec-16-19 03:44PM  
Dec-10-19 11:40AM  
Dec-07-19 11:31AM  
Dec-04-19 08:03PM  
Nov-26-19 07:30AM  
Nov-13-19 11:00AM  
07:30AM  
05:51AM  
Nov-08-19 11:31AM  
Nov-07-19 09:25AM  
08:00AM  
Oct-31-19 10:33AM  
Oct-30-19 09:15AM  
Oct-28-19 09:26AM  
Oct-25-19 07:30AM  
Oct-11-19 11:01AM  
Oct-02-19 09:15AM  
Sep-24-19 06:09PM  
Sep-19-19 07:30AM  
Sep-17-19 07:30AM  
Sep-07-19 09:30AM  
Sep-05-19 07:44AM  
Aug-30-19 06:14PM  
Aug-19-19 09:30AM  
Aug-16-19 07:15PM  
Aug-09-19 11:02AM  
Aug-08-19 06:12PM  
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STACK DAVID MCEO and ChairmanOct 16Option Exercise10.8130,000324,300203,377Oct 16 04:26 PM
STACK DAVID MCEO and ChairmanOct 16Sale55.5630,0001,666,800173,377Oct 16 04:26 PM
STACK DAVID MCEO and ChairmanOct 15Option Exercise10.8130,000324,300203,377Oct 16 04:26 PM
STACK DAVID MCEO and ChairmanOct 15Sale55.0030,0001,650,000173,377Oct 16 04:26 PM
STACK DAVID MCEO and ChairmanOct 14Option Exercise10.8130,000324,300203,377Oct 16 04:26 PM
STACK DAVID MCEO and ChairmanOct 14Sale55.5330,0001,665,900173,377Oct 16 04:26 PM
PACE GARY WDirectorSep 25Option Exercise16.6770,0001,166,900129,949Sep 29 05:16 PM
Williams Kristen MarieChief Administrative OfficerSep 17Option Exercise39.1927,8711,092,26852,758Sep 17 07:13 PM
REINHARDT MAXPresidentSep 17Option Exercise42.5425,0001,063,50039,000Sep 21 06:23 PM
REINHARDT MAXPresidentSep 17Sale59.8125,4201,520,31814,000Sep 21 06:23 PM
Williams Kristen MarieChief Administrative OfficerSep 17Sale59.8227,8711,667,29024,887Sep 17 07:13 PM
Riker Lauren BullaroVice President, FinanceSep 16Option Exercise10.813,00032,43016,181Sep 17 07:10 PM
Williams Kristen MarieChief Administrative OfficerSep 16Option Exercise39.1927,8531,091,56052,740Sep 17 07:13 PM
Riker Lauren BullaroVice President, FinanceSep 16Sale60.343,000181,02013,181Sep 17 07:10 PM
Williams Kristen MarieChief Administrative OfficerSep 16Sale60.1427,8531,675,15024,887Sep 17 07:13 PM
Williams Kristen MarieChief Administrative OfficerSep 15Option Exercise39.1927,8531,091,56052,740Sep 17 07:13 PM
Williams Kristen MarieChief Administrative OfficerSep 15Sale59.3927,8531,654,05824,887Sep 17 07:13 PM
Wicki AndreasDirectorSep 09Sale62.022,216137,436692,970Sep 11 08:03 PM
STACK DAVID MCEO and ChairmanAug 17Sale61.9115,000928,619173,377Aug 19 05:44 PM
Wicki AndreasDirectorAug 13Sale61.4734,9042,145,549695,186Aug 13 08:58 PM
Wicki AndreasDirectorAug 12Sale60.82113,5006,903,070730,090Aug 13 08:58 PM
Riker Lauren BullaroVice President, FinanceAug 11Option Exercise10.348,18084,58120,813Aug 13 04:35 PM
Wicki AndreasDirectorAug 11Sale61.32106,7726,546,747843,590Aug 13 08:58 PM
Riker Lauren BullaroVice President, FinanceAug 11Sale60.508,180494,89013,181Aug 13 04:35 PM
LARANJEIRA CHARLES ANTHONYSVP, Technical OperationsAug 03Option Exercise44.102,500110,25022,750Aug 05 05:16 PM
LARANJEIRA CHARLES ANTHONYSVP, Technical OperationsAug 03Sale52.682,500131,70020,796Aug 05 05:16 PM
STACK DAVID MCEO and ChairmanJul 15Sale56.8812,000682,560188,377Jul 17 05:44 PM
Riker Lauren BullaroVice President, FinanceJun 29Option Exercise10.346,00062,04018,633Jul 01 09:20 PM
LARANJEIRA CHARLES ANTHONYSVP, Technical OperationsJun 29Option Exercise42.0756,2502,366,58880,351Jul 01 09:17 PM
Riker Lauren BullaroVice President, FinanceJun 29Sale49.476,000296,80012,633Jul 01 09:20 PM
LARANJEIRA CHARLES ANTHONYSVP, Technical OperationsJun 29Sale50.2760,1013,021,31420,250Jul 01 09:17 PM
STACK DAVID MCEO and ChairmanJun 08Sale48.1217,111823,402166,909Jun 08 09:09 PM
Brege LauraDirectorJun 05Sale48.702,100102,2706,661Jun 08 09:04 PM
Riker Lauren BullaroVice President, FinanceJun 05Sale48.371,75284,7447,833Jun 08 09:08 PM
Williams Kristen MarieChief Administrative OfficerJun 05Sale48.615,904286,99310,887Jun 08 09:10 PM
Williams Kristen MarieChief Administrative OfficerJun 04Sale46.332,402111,28716,791Jun 08 09:10 PM
STACK DAVID MCEO and ChairmanJun 04Sale46.3314,314663,182184,020Jun 08 09:09 PM
Riker Lauren BullaroVice President, FinanceJun 04Sale46.3387940,7259,585Jun 08 09:08 PM
McLoughlin DennisChief Commercial OfficerJun 04Sale46.331,44767,04114,898Jun 08 09:07 PM
Reinhart Charles A. IIIChief Financial OfficerJun 04Sale46.331,48968,98714,847Jun 08 09:07 PM
LARANJEIRA CHARLES ANTHONYSVP, Technical OperationsJun 04Sale46.3386339,98410,101Jun 08 09:06 PM
HASTINGS PAUL JDirectorJun 04Sale47.462,02596,1074,856Jun 08 09:05 PM
Riker Lauren BullaroVice President, FinanceMay 21Option Exercise10.342,00020,68012,464May 21 07:19 PM
Riker Lauren BullaroVice President, FinanceMay 21Sale45.262,00090,52010,464May 21 07:19 PM
Riker Lauren BullaroVice President, FinanceMay 19Option Exercise10.342,00020,68012,464May 21 07:19 PM
Riker Lauren BullaroVice President, FinanceMay 19Sale42.812,00085,62010,464May 21 07:19 PM
PACE GARY WDirectorMar 12Option Exercise4.4621,73696,84558,689Mar 16 05:54 PM
LONGENECKER JOHN P PHDDirectorMar 12Option Exercise1.613,7366,01516,497Mar 16 05:53 PM
WINSTON ROYChief Clinical OfficerMar 11Buy36.502,50091,25025,237Mar 12 07:18 PM
STACK DAVID MCEO and ChairmanFeb 21Option Exercise3.3835,856121,189198,334Feb 25 04:55 PM
Riker Lauren BullaroVice President, FinanceFeb 10Option Exercise10.813,00032,43013,464Feb 12 04:41 PM
Riker Lauren BullaroVice President, FinanceFeb 10Sale48.813,000146,43010,464Feb 12 04:41 PM
Riker Lauren BullaroVice President, FinanceFeb 07Option Exercise10.811701,83810,634Feb 10 06:19 PM
Riker Lauren BullaroVice President, FinanceFeb 07Sale46.811707,95810,464Feb 10 06:19 PM
Riker Lauren BullaroVice President, FinanceFeb 06Option Exercise10.818308,97211,294Feb 10 06:19 PM
Riker Lauren BullaroVice President, FinanceFeb 06Sale46.8183038,85210,464Feb 10 06:19 PM
STACK DAVID MCEO and ChairmanJan 15Option Exercise10.8125,000270,25026,208Jan 17 06:13 PM
STACK DAVID MCEO and ChairmanJan 15Sale42.6825,0001,066,9681,208Jan 17 06:13 PM
STACK DAVID MCEO and ChairmanDec 26Option Exercise3.5520,00071,000162,299Dec 30 04:05 PM
Riker Lauren BullaroVice President, FinanceDec 23Option Exercise10.811,00010,81011,464Dec 26 04:08 PM
Riker Lauren BullaroVice President, FinanceDec 23Sale45.921,00045,92010,464Dec 26 04:08 PM
McLoughlin DennisChief Commercial OfficerDec 16Sale45.793,671168,10816,116Dec 18 06:54 PM
LONGENECKER JOHN P PHDDirectorDec 02Option Exercise1.614,0006,44014,061Dec 04 04:46 PM
LONGENECKER JOHN P PHDDirectorDec 02Sale46.131,30059,97212,761Dec 04 04:46 PM
Riker Lauren BullaroVice President, FinanceNov 20Option Exercise10.811,00010,81011,640Nov 22 07:28 PM
Riker Lauren BullaroVice President, FinanceNov 20Sale44.141,17651,90910,464Nov 22 07:28 PM
STACK DAVID MCEO and ChairmanNov 15Option Exercise10.8125,000270,25026,208Nov 19 04:16 PM
STACK DAVID MCEO and ChairmanNov 15Sale42.8125,0001,070,2501,208Nov 19 04:16 PM
STACK DAVID MCEO and ChairmanNov 15Sale42.8145,0001,926,450142,299Nov 19 04:16 PM
Riker Lauren BullaroVice President, FinanceNov 11Option Exercise10.365,00051,78515,640Nov 12 05:12 PM
Riker Lauren BullaroVice President, FinanceNov 11Sale43.595,000217,95010,640Nov 12 05:12 PM
Scranton RichardChief Scientific OfficerNov 08Option Exercise14.3719,448279,39335,509Nov 12 05:10 PM
Scranton RichardChief Scientific OfficerNov 08Sale45.0019,448875,16016,061Nov 12 05:10 PM
CYTK Cytokinetics, Incorporated daily Stock Chart
CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.37 Insider Own0.80% Shs Outstand70.50M Perf Week-0.49%
Market Cap1.14B Forward P/E- EPS next Y-2.08 Insider Trans-41.51% Shs Float69.97M Perf Month-25.33%
Income-140.40M PEG- EPS next Q-0.30 Inst Own85.50% Short Float12.55% Perf Quarter-31.99%
Sales18.70M P/S61.15 EPS this Y-8.20% Inst Trans0.75% Short Ratio5.77 Perf Half Y4.73%
Book/sh-1.31 P/B- EPS next Y-1.00% ROA-58.10% Target Price- Perf Year47.79%
Cash/sh3.05 P/C5.37 EPS next 5Y15.00% ROE363.30% 52W Range7.72 - 30.14 Perf YTD54.48%
Dividend- P/FCF- EPS past 5Y-38.80% ROI-83.50% 52W High-45.62% Beta1.32
Dividend %- Quick Ratio9.60 Sales past 5Y-10.60% Gross Margin- 52W Low112.17% ATR1.73
Employees156 Current Ratio9.60 Sales Q/Q-49.30% Oper. Margin- RSI (14)38.01 Volatility5.20% 8.06%
OptionableYes Debt/Eq- EPS Q/Q-22.80% Profit Margin- Rel Volume0.46 Prev Close16.22
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume1.52M Price16.39
Recom2.00 SMA20-17.84% SMA50-24.77% SMA200-11.97% Volume694,701 Change1.05%
Jul-10-20Initiated Raymond James Strong Buy $39
May-05-20Initiated Mizuho Buy $31
Apr-09-20Upgrade Morgan Stanley Equal-Weight → Overweight $25
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Dec-31-14Reiterated ROTH Capital Buy $13 → $18
Nov-04-14Upgrade MLV & Co Hold → Buy $9
Apr-28-14Reiterated Needham Buy $25 → $15
Apr-25-14Downgrade MLV & Co Buy → Hold $26 → $5
Oct-22-20 12:33PM  
08:43AM  
Oct-21-20 04:00PM  
Oct-13-20 03:24PM  
Oct-09-20 12:46PM  
Oct-08-20 04:13PM  
04:11PM  
10:14AM  
08:30AM  
08:30AM  
Oct-05-20 04:26PM  
04:00PM  
08:48AM  
07:30AM  
Oct-02-20 07:30AM  
Sep-28-20 05:25PM  
Sep-25-20 08:56AM  
Sep-24-20 04:00PM  
07:30AM  
Sep-23-20 07:30AM  
Sep-17-20 07:30AM  
Sep-02-20 04:00PM  
Aug-26-20 07:30AM  
Aug-18-20 07:30AM  
Aug-06-20 04:00PM  
Jul-30-20 12:33PM  
Jul-24-20 08:36AM  
Jul-23-20 04:00PM  
Jul-21-20 04:00PM  
04:00PM  
Jul-20-20 06:39PM  
Jul-16-20 11:32PM  
08:31AM  
Jul-15-20 04:00PM  
07:30AM  
Jul-14-20 07:30AM  
Jul-13-20 07:30AM  
Jul-10-20 10:10AM  
Jul-01-20 04:00PM  
Jun-30-20 11:45AM  
Jun-16-20 09:48PM  
Jun-08-20 04:00PM  
Jun-04-20 11:35AM  
May-27-20 07:30AM  
May-11-20 12:21PM  
May-08-20 08:30AM  
08:30AM  
May-07-20 04:00PM  
04:00PM  
May-06-20 04:00PM  
May-05-20 11:46AM  
May-04-20 05:59PM  
07:58AM  
Apr-30-20 08:33AM  
Apr-29-20 12:34PM  
Apr-22-20 04:00PM  
Apr-14-20 07:30AM  
Apr-08-20 04:00PM  
Apr-01-20 07:32AM  
Mar-30-20 01:35PM  
07:30AM  
Mar-20-20 04:00PM  
Mar-04-20 07:30AM  
Mar-03-20 05:15PM  
04:00PM  
07:30AM  
Feb-28-20 07:30AM  
Feb-26-20 08:30AM  
08:30AM  
Feb-25-20 12:30PM  
Feb-20-20 07:30AM  
Feb-18-20 04:00PM  
Feb-13-20 12:31PM  
Feb-12-20 10:55AM  
Feb-06-20 04:30AM  
Jan-30-20 06:59AM  
Jan-22-20 07:30AM  
Jan-17-20 09:26AM  
Jan-13-20 07:30AM  
Jan-10-20 08:10PM  
Jan-06-20 07:30AM  
Jan-03-20 05:43PM  
Dec-18-19 07:30AM  
Dec-10-19 10:45AM  
Dec-09-19 10:03AM  
Dec-05-19 07:30AM  
Nov-27-19 04:00PM  
09:45AM  
Nov-26-19 04:00PM  
Nov-18-19 09:00AM  
09:00AM  
Nov-11-19 12:14PM  
09:00AM  
Nov-08-19 07:30AM  
Nov-06-19 04:05PM  
Nov-05-19 07:30AM  
Nov-01-19 11:08AM  
Oct-31-19 05:15PM  
04:00PM  
Oct-24-19 04:00PM  
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blum Robert IPresident & CEOOct 13Option Exercise6.005,00030,000309,868Oct 14 04:53 PM
Blum Robert IPresident & CEOOct 13Sale15.945,00079,686304,868Oct 14 04:53 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 08Sale17.451,25821,952152,182Oct 08 05:08 PM
COSTA SANTO JDirectorOct 05Option Exercise9.4515,000141,75015,000Oct 05 05:53 PM
HENDERSON JOHN TDirectorOct 05Option Exercise12.963,00038,8802,399Oct 05 09:03 PM
Jaw ChingSVP Finance & CFOOct 05Option Exercise10.0327,500275,70088,300Oct 05 08:23 PM
Kaye Edward M. MDDirectorOct 05Option Exercise7.6120,000152,20020,000Oct 05 08:38 PM
SMITH SANDFORD DDirectorOct 05Option Exercise7.375,93643,7485,936Oct 05 09:11 PM
PARSHALL B LYNNEDirectorOct 05Option Exercise7.2350,311363,89820,000Oct 06 04:58 PM
SMITH SANDFORD DDirectorOct 05Sale30.005,936178,0800Oct 05 09:11 PM
HENDERSON JOHN TDirectorOct 05Sale29.003,00087,000899Oct 05 09:03 PM
PARSHALL B LYNNEDirectorOct 05Sale30.0050,3111,509,3300Oct 06 04:58 PM
Jaw ChingSVP Finance & CFOOct 05Sale30.0027,500825,00073,300Oct 05 08:23 PM
COSTA SANTO JDirectorOct 05Sale30.0015,000450,0000Oct 05 05:53 PM
Kaye Edward M. MDDirectorOct 05Sale30.0020,000600,0000Oct 05 08:38 PM
Blum Robert IPresident & CEOOct 02Option Exercise6.005,00030,000309,868Oct 02 05:48 PM
Blum Robert IPresident & CEOOct 02Sale22.535,000112,646304,868Oct 02 05:48 PM
Blum Robert IPresident & CEOSep 21Option Exercise6.005,00030,000309,868Sep 21 05:16 PM
Blum Robert IPresident & CEOSep 21Sale20.975,000104,835304,868Sep 21 05:16 PM
Blum Robert IPresident & CEOSep 11Option Exercise6.005,00030,000309,868Sep 11 05:05 PM
Blum Robert IPresident & CEOSep 11Sale22.955,000114,736304,868Sep 11 05:05 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 10Sale22.8599522,736153,440Sep 11 04:37 PM
Blum Robert IPresident & CEOSep 04Option Exercise6.005,00030,000309,868Sep 04 05:29 PM
Blum Robert IPresident & CEOSep 04Sale22.375,000111,855304,868Sep 04 05:29 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselAug 21Option Exercise7.0310,00070,30040,000Aug 21 05:34 PM
Jaw ChingSVP Finance & CFOAug 21Option Exercise7.5425,000188,40088,300Aug 21 05:41 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselAug 21Sale25.0010,000250,00030,000Aug 21 05:34 PM
Jaw ChingSVP Finance & CFOAug 21Sale25.0025,000625,00073,300Aug 21 05:41 PM
Blum Robert IPresident & CEOAug 18Option Exercise6.005,00030,000309,868Aug 20 04:27 PM
Blum Robert IPresident & CEOAug 18Sale23.485,000117,422304,868Aug 20 04:27 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 13Sale21.8559913,088154,435Aug 14 05:16 PM
Blum Robert IPresident & CEOAug 05Option Exercise6.005,00030,000309,868Aug 07 04:39 PM
Blum Robert IPresident & CEOAug 05Sale22.125,000110,621304,868Aug 07 04:39 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselJul 29Option Exercise7.0310,00070,30040,000Jul 30 07:57 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselJul 29Sale23.0710,000230,72830,000Jul 30 07:57 PM
Blum Robert IPresident & CEOJul 28Option Exercise6.005,00030,000309,868Jul 30 07:56 PM
Blum Robert IPresident & CEOJul 28Sale23.775,000118,829304,868Jul 30 07:56 PM
Blum Robert IPresident & CEOJul 16Option Exercise6.005,00030,000309,868Jul 17 05:15 PM
Blum Robert IPresident & CEOJul 16Sale27.365,000136,806304,868Jul 17 05:15 PM
SMITH SANDFORD DDirectorJul 15Option Exercise6.216,66741,4026,667Jul 17 05:14 PM
SMITH SANDFORD DDirectorJul 15Sale29.006,667193,3430Jul 17 05:14 PM
SMITH SANDFORD DDirectorJul 10Option Exercise6.216,66741,4026,667Jul 13 05:34 PM
SMITH SANDFORD DDirectorJul 10Sale28.006,667186,6760Jul 13 05:34 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 09Sale26.961,58742,786155,034Jul 10 08:09 PM
SMITH SANDFORD DDirectorJul 08Option Exercise6.211,4348,9051,434Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 08Sale27.001,43438,7180Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 07Option Exercise6.4911,74276,2386,510Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 07Sale26.4511,742310,5240Jul 09 05:37 PM
Blum Robert IPresident & CEOJul 06Option Exercise6.005,00030,000309,868Jul 08 05:08 PM
Blum Robert IPresident & CEOJul 06Sale24.855,000124,255304,868Jul 08 05:08 PM
Blum Robert IPresident & CEOJun 24Option Exercise6.075,00030,354308,689Jun 26 04:41 PM
Blum Robert IPresident & CEOJun 24Sale23.865,000119,309304,868Jun 26 04:41 PM
COSTA SANTO JDirectorJun 22Option Exercise7.6120,000152,20020,000Jun 24 05:40 PM
PARSHALL B LYNNEDirectorJun 22Option Exercise5.3416,51088,14710,000Jun 23 05:00 PM
SMITH SANDFORD DDirectorJun 22Option Exercise4.4410,00044,4005,000Jun 22 05:43 PM
PARSHALL B LYNNEDirectorJun 22Sale25.0016,510412,7500Jun 23 05:00 PM
SMITH SANDFORD DDirectorJun 22Sale24.5010,000245,0000Jun 22 05:43 PM
COSTA SANTO JDirectorJun 22Sale25.0020,000500,0000Jun 24 05:40 PM
SMITH SANDFORD DDirectorJun 17Option Exercise6.806,90746,9944,166Jun 17 06:07 PM
SMITH SANDFORD DDirectorJun 17Sale23.006,907158,8610Jun 17 06:07 PM
SMITH SANDFORD DDirectorJun 15Option Exercise6.306,66641,9966,666Jun 15 05:57 PM
SMITH SANDFORD DDirectorJun 15Sale22.006,666146,6520Jun 15 05:57 PM
SMITH SANDFORD DDirectorJun 12Option Exercise4.4215,04566,48010,879Jun 12 06:31 PM
SMITH SANDFORD DDirectorJun 12Sale20.8615,045313,9070Jun 12 06:31 PM
Blum Robert IPresident & CEOJun 11Option Exercise6.305,00031,500309,868Jun 12 06:32 PM
Blum Robert IPresident & CEOJun 11Sale21.475,000107,354304,868Jun 12 06:32 PM
Blum Robert IPresident & CEOMay 29Option Exercise6.305,00031,500308,633May 29 07:45 PM
Blum Robert IPresident & CEOMay 29Sale20.105,000100,503303,633May 29 07:45 PM
HENDERSON JOHN TDirectorMay 19Option Exercise16.863,33356,1943,583May 20 05:04 PM
GAGE L PATRICKDirectorMay 18Option Exercise16.863,33356,19423,333May 20 05:04 PM
Blum Robert IPresident & CEOMay 18Option Exercise6.304,18926,391307,822May 18 07:37 PM
Blum Robert IPresident & CEOMay 18Sale22.155,000110,732303,633May 18 07:37 PM
COSTA SANTO JDirectorMay 11Option Exercise8.4929,999254,58720,000May 12 04:22 PM
COSTA SANTO JDirectorMay 11Sale19.8229,999594,6870May 12 04:22 PM
COSTA SANTO JDirectorMay 05Option Exercise6.128,33250,9924,166May 06 06:39 PM
COSTA SANTO JDirectorMay 05Sale17.008,332141,6440May 06 06:39 PM
Blum Robert IPresident & CEOMay 01Sale14.345,00071,678304,444May 01 07:06 PM
WIERENGA WENDALLDirectorApr 28Option Exercise10.249,999102,3906,666Apr 29 06:25 PM
WIERENGA WENDALLDirectorApr 28Sale16.009,999159,9840Apr 29 06:25 PM
GAGE L PATRICKDirectorMar 06Sale14.828,000118,59220,000Mar 20 03:21 PM
BVF PARTNERS L P/IL10% OwnerFeb 13Sale15.791,072,03016,923,923424,419Feb 18 06:00 PM
Blum Robert IPresident & CEOJan 15Sale12.964,95064,159224,107Jan 16 04:53 PM
Blum Robert IPresident & CEODec 16Sale10.226,00061,326229,057Dec 17 04:24 PM
BVF PARTNERS L P/IL10% OwnerDec 11Buy9.52118,4131,126,7003,617,776Dec 12 07:49 PM
BVF PARTNERS L P/IL10% OwnerDec 10Buy9.40223,6592,102,3953,557,673Dec 12 07:49 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 05Sale9.801,50014,700121,350Dec 06 04:42 PM
HENDERSON JOHN TDirectorNov 19Buy8.576,00051,4276,250Jan 02 02:22 PM
Blum Robert IPresident & CEONov 15Sale8.086,00048,508235,057Nov 18 04:12 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 07Sale9.981,50014,970122,850Nov 08 05:08 PM
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-21.57 Insider Own20.50% Shs Outstand77.71M Perf Week-5.56%
Market Cap27.39B Forward P/E- EPS next Y-12.97 Insider Trans-3.81% Shs Float63.31M Perf Month8.11%
Income-1457.80M PEG- EPS next Q-4.12 Inst Own63.30% Short Float3.93% Perf Quarter33.48%
Sales224.70M P/S121.92 EPS this Y-39.00% Inst Trans9.81% Short Ratio10.16 Perf Half Y81.21%
Book/sh32.64 P/B9.16 EPS next Y18.30% ROA-48.70% Target Price243.50 Perf Year115.03%
Cash/sh34.41 P/C8.69 EPS next 5Y24.00% ROE-73.50% 52W Range118.55 - 322.98 Perf YTD80.38%
Dividend- P/FCF- EPS past 5Y- ROI-85.60% 52W High-7.42% Beta1.21
Dividend %- Quick Ratio6.10 Sales past 5Y101.10% Gross Margin70.40% 52W Low152.21% ATR11.04
Employees4200 Current Ratio6.20 Sales Q/Q-73.00% Oper. Margin- RSI (14)55.67 Volatility3.90% 3.76%
OptionableYes Debt/Eq0.13 EPS Q/Q-201.50% Profit Margin- Rel Volume0.98 Prev Close303.79
ShortableYes LT Debt/Eq0.12 Earnings- Payout- Avg Volume244.82K Price299.00
Recom2.00 SMA200.40% SMA5012.30% SMA20053.33% Volume239,014 Change-1.58%
Jul-10-20Downgrade CLSA Buy → Outperform
Mar-13-20Upgrade Macquarie Underperform → Neutral
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
Sep-25-18Initiated Leerink Partners Outperform
May-17-18Reiterated Maxim Group Buy $200 → $225
May-14-18Initiated Credit Suisse Outperform
Apr-13-18Initiated Piper Jaffray Overweight $200
Apr-10-18Reiterated Maxim Group Buy $160 → $200
Oct-09-20 07:05AM  
Oct-06-20 07:00AM  
Oct-01-20 12:00PM  
08:15AM  
Sep-27-20 06:12AM  
Sep-21-20 07:00AM  
Sep-17-20 06:05PM  
Sep-10-20 09:00AM  
Sep-09-20 07:00AM  
Sep-04-20 09:15AM  
Aug-27-20 08:02AM  
07:00AM  
Aug-25-20 07:00AM  
Aug-24-20 08:08AM  
Aug-07-20 12:00PM  
Aug-06-20 04:05PM  
Aug-05-20 07:00AM  
Jul-27-20 09:15AM  
Jul-24-20 06:12PM  
Jul-20-20 07:53AM  
06:30AM  
Jul-17-20 09:00AM  
Jul-16-20 10:31AM  
Jul-15-20 05:00PM  
04:19AM  
Jul-14-20 03:43PM  
08:43AM  
Jul-13-20 10:51AM  
10:11AM  
07:53AM  
06:40AM  
02:03AM  
Jul-12-20 09:30PM  
08:00PM  
Jul-10-20 11:11AM  
Jul-05-20 04:04PM  
Jul-02-20 07:00AM  
Jul-01-20 06:00PM  
08:12AM  
07:00AM  
Jun-30-20 07:30PM  
Jun-22-20 09:00AM  
Jun-19-20 12:27AM  
Jun-18-20 07:30AM  
Jun-12-20 02:30AM  
Jun-05-20 07:30AM  
Jun-03-20 07:15AM  
May-29-20 08:00AM  
08:00AM  
May-26-20 04:05PM  
04:04AM  
02:00AM  
May-21-20 07:00AM  
May-20-20 07:00AM  
May-15-20 07:00AM  
May-14-20 05:45PM  
09:00AM  
May-11-20 04:05PM  
Apr-29-20 05:00PM  
Apr-20-20 04:05PM  
Apr-13-20 04:05PM  
Apr-10-20 06:00PM  
Mar-26-20 02:30PM  
Mar-25-20 09:00AM  
Mar-19-20 05:09PM  
Mar-10-20 12:57PM  
Mar-09-20 12:30PM  
Mar-07-20 10:31AM  
Mar-02-20 04:05PM  
Feb-27-20 07:14AM  
Feb-25-20 07:00AM  
Feb-18-20 10:49AM  
Jan-21-20 07:00AM  
Jan-13-20 07:00AM  
Jan-08-20 07:30AM  
Jan-06-20 08:25AM  
Jan-03-20 02:11PM  
08:53AM  
Jan-02-20 08:15AM  
Dec-30-19 05:17PM  
Dec-28-19 09:30AM  
Dec-27-19 10:30PM  
Dec-22-19 06:00PM  
Dec-20-19 09:25AM  
Dec-19-19 04:40PM  
Dec-16-19 07:00AM  
Dec-13-19 07:00AM  
Dec-08-19 04:45PM  
Dec-02-19 06:02PM  
Nov-29-19 03:30PM  
Nov-26-19 05:54PM  
07:00AM  
Nov-23-19 05:00AM  
Nov-16-19 08:43AM  
Nov-15-19 05:34PM  
10:09AM  
04:30AM  
02:00AM  
Nov-14-19 04:20PM  
04:01PM  
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang XiaodongChair, Scientific Advisory BrdOct 16Sale320.005,0001,600,0000Oct 20 04:44 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Option Exercise6.5014,00091,00014,000Oct 07 04:50 PM
Wang XiaodongChair, Scientific Advisory BrdOct 05Sale300.005,0001,500,0000Oct 07 04:56 PM
Wu XiaobinPresident & GM ChinaOct 05Sale300.004,0001,200,0000Oct 07 04:52 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Sale299.6014,0004,194,4130Oct 07 04:50 PM
Huang JaneCMO, HematologySep 29Option Exercise29.491,50044,2351,500Oct 01 04:52 PM
Huang JaneCMO, HematologySep 29Sale280.381,500420,5680Oct 01 04:52 PM
OYLER JOHNChief Executive OfficerSep 29Sale280.8223,3036,544,0300Sep 30 04:53 PM
OYLER JOHNChief Executive OfficerSep 28Sale280.0731,0008,682,0630Sep 30 04:53 PM
Wang XiaodongChair, Scientific Advisory BrdSep 25Sale280.425,0001,402,1160Sep 29 04:59 PM
Wu XiaobinPresident & GM ChinaSep 25Sale280.354,0001,121,4060Sep 29 04:57 PM
Wu XiaobinPresident & GM ChinaSep 17Sale260.334,0001,041,3270Sep 21 04:50 PM
Wang XiaodongChair, Scientific Advisory BrdSep 17Sale260.275,0001,301,3560Sep 21 04:53 PM
OYLER JOHNChief Executive OfficerSep 16Sale254.7727,2756,948,8070Sep 16 05:12 PM
OYLER JOHNChief Executive OfficerSep 15Sale254.2634,2148,699,3810Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Option Exercise6.5014,00091,00014,000Sep 16 05:10 PM
OYLER JOHNChief Executive OfficerSep 14Sale250.2519,7394,939,7820Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Sale250.2714,0003,503,7640Sep 16 05:10 PM
Huang JaneCMO, HematologySep 03Sale233.073,128729,0450Sep 08 04:44 PM
OYLER JOHNChief Executive OfficerSep 02Sale229.2227,8076,374,0240Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerSep 01Sale233.7920,2744,739,8090Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerAug 31Sale240.8612,9613,121,7650Sep 02 05:44 PM
Huang JaneCMO, HematologyAug 28Option Exercise29.493,00088,4703,000Sep 01 04:41 PM
Huang JaneCMO, HematologyAug 28Sale242.213,000726,6260Sep 01 04:41 PM
OYLER JOHNChief Executive OfficerAug 21Sale240.1940,7889,796,7750Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 20Sale234.6221,5235,049,7490Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 19Sale234.5629,8667,005,2650Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 14Sale211.158,7051,838,0340Aug 14 05:30 PM
OYLER JOHNChief Executive OfficerAug 13Sale214.4814,4433,097,7620Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Option Exercise31.592,89791,5162,897Aug 12 05:02 PM
OYLER JOHNChief Executive OfficerAug 12Sale212.1019,8204,203,7660Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Sale212.002,897614,1650Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Option Exercise31.591,90360,1161,903Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Sale213.041,903405,4090Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Option Exercise31.592,20069,4982,200Aug 12 05:02 PM
Wang XiaodongChair, Scientific Advisory BrdAug 10Sale211.064,000844,2290Aug 12 04:38 PM
Chen Timothy Yung-ChengDirectorAug 10Sale214.042,200470,8860Aug 12 05:02 PM
OYLER JOHNChief Executive OfficerAug 05Sale223.2717,2543,852,2730Aug 05 05:43 PM
OYLER JOHNChief Executive OfficerAug 04Sale220.4315,3833,390,9510Aug 05 05:30 PM
OYLER JOHNChief Executive OfficerAug 03Sale221.7825,1765,583,5750Aug 05 05:30 PM
Huang JaneCMO, HematologyJul 29Option Exercise94.953,000284,8353,000Jul 31 04:24 PM
Huang JaneCMO, HematologyJul 29Sale209.933,000629,7870Jul 31 04:24 PM
OYLER JOHNChief Executive OfficerJul 22Sale238.3427,7486,613,5030Jul 22 06:22 PM
OYLER JOHNChief Executive OfficerJul 21Sale251.8326,4136,651,6950Jul 22 06:14 PM
OYLER JOHNChief Executive OfficerJul 20Sale251.8528,7627,243,7840Jul 22 06:14 PM
Wang XiaodongChair, Scientific Advisory BrdJul 20Sale251.3112,0003,015,7400Jul 22 04:47 PM
Wang XiaodongChair, Scientific Advisory BrdJul 20Sale251.985,0001,259,8960Jul 22 04:47 PM
Wu XiaobinPresident & GM ChinaJul 20Sale250.162,600650,4070Jul 21 04:50 PM
Wu XiaobinPresident & GM ChinaJul 17Sale245.74700172,0150Jul 21 04:50 PM
Wu XiaobinPresident & GM ChinaJul 15Sale241.112,700650,9980Jul 15 05:14 PM
Wu XiaobinPresident & GM ChinaJul 13Sale220.003,000660,0000Jul 15 05:14 PM
OYLER JOHNChief Executive OfficerJul 08Sale201.3917,5293,530,2060Jul 08 05:20 PM
Huang JaneCMO, HematologyJul 07Option Exercise160.403,921628,9283,921Jul 09 04:43 PM
OYLER JOHNChief Executive OfficerJul 07Sale198.8619,0233,782,9870Jul 08 05:20 PM
Huang JaneCMO, HematologyJul 07Sale200.003,921784,2000Jul 09 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 07Sale200.006,0001,200,0000Jul 09 04:45 PM
OYLER JOHNChief Executive OfficerJul 06Sale197.1117,3623,422,2620Jul 08 05:20 PM
OYLER JOHNChief Executive OfficerJul 01Sale191.573,816731,0160Jul 01 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 01Sale190.754,847924,5720Jul 06 04:52 PM
Huang JaneCMO, HematologyJun 29Option Exercise29.491,50044,2351,500Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 29Sale192.601,435276,3740Jul 01 04:43 PM
Liang HowardCFO & Chief Strategy OfficerJun 29Sale191.2330057,3680Jul 01 04:38 PM
Huang JaneCMO, HematologyJun 29Sale190.831,935369,2500Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Option Exercise160.402,079333,4722,079Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Sale200.292,079416,3970Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 24Sale187.3414,3812,694,1560Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 23Sale186.386,0001,118,2980Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 23Sale186.8815,0702,816,22214,381Jun 24 08:23 PM
OYLER JOHNChief Executive OfficerJun 22Sale182.4310,2811,875,60529,451Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 22Sale181.335,000906,6730Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 10Sale175.07900157,5630Jun 12 04:14 PM
Liang HowardCFO & Chief Strategy OfficerJun 08Sale170.8445377,3910Jun 10 05:17 PM
Wu XiaobinPresident & GM ChinaJun 08Sale170.832,800478,3170Jun 10 05:15 PM
Huang JaneCMO, HematologyJun 08Sale170.84631107,8000Jun 10 05:13 PM
Wang XiaodongChair, Scientific Advisory BrdJun 08Sale170.916,0001,025,4550Jun 10 05:12 PM
Huang JaneCMO, HematologyMay 29Option Exercise29.491,50044,2351,500Jun 02 04:11 PM
Huang JaneCMO, HematologyMay 29Sale163.861,500245,7840Jun 02 04:11 PM
Glazer Donald W.DirectorMay 19Sale169.8410,0001,698,4000May 21 04:08 PM
OYLER JOHNChief Executive OfficerMay 01Sale141.434,635655,5370May 05 04:48 PM
Wu XiaobinPresident & GM ChinaMay 01Sale141.337,024992,7110May 05 04:46 PM
Huang JaneCMO, HematologyApr 29Option Exercise29.491,50044,2351,500Apr 30 04:04 PM
Huang JaneCMO, HematologyApr 29Sale162.301,500243,4500Apr 30 04:04 PM
Huang JaneCMO, HematologyApr 16Option Exercise29.491,50044,2351,500Apr 17 04:04 PM
Huang JaneCMO, HematologyApr 16Sale160.001,500240,0000Apr 17 04:04 PM
Wang XiaodongChair, Scientific Advisory BrdMar 04Sale157.145,000785,6810Mar 06 08:30 PM
Huang JaneCMO, HematologyFeb 18Option Exercise29.491,50044,2351,500Feb 20 04:13 PM
Huang JaneCMO, HematologyFeb 18Sale170.251,500255,3800Feb 20 04:13 PM
Huang JaneCMO, HematologyJan 21Option Exercise29.491,50044,2351,500Jan 22 06:59 PM
Huang JaneCMO, HematologyJan 21Sale170.691,500256,0420Jan 22 06:59 PM
OYLER JOHNChief Executive OfficerDec 17Sale160.6262,25910,000,1000Dec 19 04:10 PM
Huang JaneCMO, HematologyDec 16Option Exercise29.491,50044,2351,500Dec 18 06:57 PM
Huang JaneCMO, HematologyDec 16Sale165.141,500247,7100Dec 18 06:57 PM
Huang JaneCMO, HematologyNov 18Option Exercise29.491,50044,2351,500Nov 20 07:19 PM
Liang HowardCFO & Chief Strategy OfficerNov 18Option Exercise6.5025,000162,50025,000Nov 20 07:20 PM
Huang JaneCMO, HematologyNov 18Sale194.491,500291,7400Nov 20 07:19 PM
Liang HowardCFO & Chief Strategy OfficerNov 18Sale194.3425,0004,858,6160Nov 20 07:20 PM
Wu XiaobinPresident & GM ChinaNov 15Sale202.051,000202,0500Nov 18 05:22 PM
Wang XiaodongChair, Scientific Advisory BrdNov 15Sale202.0539579,8100Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 15Sale202.051,496302,2670Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 14Sale193.572,605504,242395Nov 18 05:24 PM
ATNX Athenex, Inc. daily Stock Chart
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.46 Insider Own7.10% Shs Outstand81.56M Perf Week-8.47%
Market Cap1.09B Forward P/E- EPS next Y-1.31 Insider Trans44.66% Shs Float59.95M Perf Month-3.05%
Income-116.40M PEG- EPS next Q-0.43 Inst Own54.20% Short Float16.23% Perf Quarter-2.55%
Sales140.80M P/S7.76 EPS this Y8.10% Inst Trans6.38% Short Ratio12.00 Perf Half Y20.40%
Book/sh1.71 P/B6.70 EPS next Y20.60% ROA-39.00% Target Price- Perf Year8.22%
Cash/sh1.22 P/C9.39 EPS next 5Y- ROE-72.20% 52W Range5.63 - 18.35 Perf YTD-25.02%
Dividend- P/FCF- EPS past 5Y-39.10% ROI-49.90% 52W High-37.60% Beta0.85
Dividend %- Quick Ratio2.80 Sales past 5Y142.30% Gross Margin39.40% 52W Low103.37% ATR0.58
Employees574 Current Ratio3.20 Sales Q/Q81.10% Oper. Margin-78.10% RSI (14)43.97 Volatility4.53% 4.40%
OptionableYes Debt/Eq0.69 EPS Q/Q-13.20% Profit Margin-82.60% Rel Volume0.62 Prev Close11.91
ShortableYes LT Debt/Eq0.68 EarningsNov 05 BMO Payout- Avg Volume811.11K Price11.45
Recom1.70 SMA20-6.97% SMA50-5.57% SMA200-1.89% Volume499,533 Change-3.86%
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Oct-25-20 07:05AM  
Oct-22-20 07:00AM  
Oct-14-20 09:51PM  
Oct-12-20 04:05PM  
Oct-09-20 07:30AM  
Oct-06-20 07:34AM  
Sep-23-20 07:00AM  
Sep-19-20 07:00AM  
Sep-10-20 01:59PM  
07:00AM  
Sep-08-20 04:01PM  
07:00AM  
Sep-06-20 10:03AM  
Sep-02-20 01:24PM  
10:40AM  
Sep-01-20 12:58PM  
10:46AM  
07:00AM  
Aug-07-20 09:02AM  
Aug-06-20 12:15PM  
07:00AM  
07:00AM  
Aug-04-20 09:30AM  
Jul-27-20 07:00AM  
Jul-08-20 09:24AM  
Jun-29-20 11:41AM  
Jun-27-20 09:28PM  
Jun-23-20 07:00AM  
Jun-22-20 08:00AM  
Jun-13-20 10:00AM  
Jun-08-20 06:19PM  
Jun-03-20 04:50PM  
Jun-02-20 06:12AM  
May-29-20 08:00AM  
May-27-20 12:40PM  
08:40AM  
May-25-20 03:45PM  
May-19-20 09:05AM  
May-12-20 12:00PM  
11:29AM  
May-09-20 01:31PM  
May-08-20 12:41PM  
May-07-20 06:47PM  
09:47AM  
08:45AM  
07:00AM  
Apr-30-20 12:34PM  
Apr-29-20 01:54PM  
Apr-23-20 08:00AM  
Apr-09-20 07:00AM  
Mar-13-20 08:10AM  
Mar-11-20 07:06AM  
Mar-10-20 07:05PM  
Mar-09-20 07:00AM  
Mar-06-20 12:00PM  
Mar-02-20 10:19AM  
Feb-27-20 10:15AM  
07:00AM  
06:00AM  
Feb-25-20 08:00AM  
Feb-20-20 12:31PM  
Feb-06-20 07:00AM  
Feb-03-20 05:01PM  
Jan-16-20 09:46AM  
05:58AM  
Jan-08-20 01:51PM  
Dec-28-19 05:17PM  
Dec-27-19 02:57PM  
Dec-22-19 01:52PM  
Dec-16-19 07:00AM  
Dec-13-19 09:46AM  
09:31AM  
08:30AM  
Dec-11-19 07:00AM  
Dec-09-19 08:10PM  
Dec-05-19 08:00AM  
Dec-02-19 05:00AM  
Nov-21-19 08:42AM  
Nov-19-19 09:05AM  
Nov-18-19 03:29AM  
Nov-07-19 08:35AM  
07:00AM  
Oct-31-19 10:34AM  
Oct-30-19 07:00AM  
Oct-28-19 03:30AM  
Oct-26-19 12:33PM  
Oct-24-19 07:00AM  
07:00AM  
Oct-21-19 04:46PM  
11:29AM  
Oct-18-19 06:49AM  
Oct-10-19 10:34PM  
Oct-07-19 12:14PM  
Sep-30-19 11:44AM  
Sep-23-19 07:00AM  
07:00AM  
07:00AM  
Sep-22-19 04:44PM  
Sep-13-19 05:15AM  
Sep-12-19 07:15AM  
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 24Buy11.951,00011,9503,145,959Sep 24 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 21Buy12.421,00012,4203,144,959Sep 21 04:53 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 14Buy11.001,800,00019,800,00013,532,467Sep 14 03:47 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 14Buy11.951,00011,9503,143,959Sep 14 04:09 PM
Fok MansonDirectorSep 12Buy11.0316,491181,8961,999,609Sep 14 04:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.911,00010,9103,142,959Sep 14 04:09 PM
Fok MansonDirectorSep 11Buy11.3913,509153,8681,983,118Sep 14 04:21 PM
WU JINNDirectorSep 11Buy11.0510,000110,500401,208Sep 14 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.992,00021,9783,141,959Sep 11 04:10 PM
YORDON JEFFREYSee RemarksSep 10Option Exercise11.0018,180199,980237,106Sep 10 04:44 PM
Davis Stephanie ADirectorSep 10Buy11.3510,000113,50020,000Sep 14 04:24 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 10Buy11.24200,0002,248,00011,732,467Sep 14 03:47 PM
Kanfer JordanDirectorSep 10Buy11.494505,1714,634Sep 11 04:20 PM
WU JINNDirectorSep 10Buy11.1520,000223,000391,208Sep 11 04:16 PM
Sze RandollChief Financial OfficerSep 10Buy11.401,00011,4006,000Sep 10 04:48 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 10Buy11.2210,000112,2003,139,959Sep 10 04:38 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 21Option Exercise4.555,00022,7503,129,959Aug 21 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 20Option Exercise4.5510,00045,5003,124,959Aug 20 04:14 PM
Kwan RudolfEVP, Chief Medical OfficerJun 22Buy12.821,00012,820143,299Jun 23 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardJun 22Buy12.812,00025,6203,114,959Jun 22 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 27Buy7.881,0007,8803,112,959Mar 27 04:30 PM
Sze RandollChief Financial OfficerMar 27Buy8.191,0008,1905,000Mar 27 04:14 PM
Fok MansonDirectorMar 25Buy7.2550,000362,5001,969,609Mar 26 05:07 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 23Buy6.641,0006,6403,111,959Mar 23 04:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 20Buy6.851,0006,8503,110,959Mar 20 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Buy6.602,00013,2003,109,959Mar 19 04:14 PM
Kwan RudolfEVP, Chief Medical OfficerMar 18Buy5.904,00023,584141,048Mar 19 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 18Buy5.782,00011,5603,107,959Mar 18 04:11 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Buy6.902,00013,8003,105,959Mar 17 04:42 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 16Buy7.612,00015,2203,103,959Mar 16 04:11 PM
TSANG Benson Kwan HungDirectorMar 13Buy8.395,00041,95010,000Mar 16 06:55 AM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.354,00033,3963,099,959Mar 12 04:11 PM
Kwan RudolfEVP, Chief Medical OfficerMar 12Buy8.192,00016,380137,048Mar 13 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.122,00016,2403,101,959Mar 13 04:13 PM
YORDON JEFFREYSee RemarksMar 12Buy8.1410,00081,430218,926Mar 12 04:15 PM
TSANG Benson Kwan HungDirectorMar 12Buy8.345,00041,7005,000Mar 13 05:23 PM
Fok MansonDirectorMar 11Buy10.2850,000513,8501,919,609Mar 11 04:21 PM
Kwan RudolfEVP, Chief Medical OfficerMar 09Buy9.792,00019,573135,048Mar 10 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 24Buy14.3973,6981,060,51411,532,467Dec 27 04:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 23Buy14.30153,2372,191,28911,458,769Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 20Buy14.14189,3222,677,01311,305,532Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 19Buy13.78263,7433,635,48411,116,210Dec 26 06:04 AM
WU JINNDirectorDec 18Option Exercise4.5520,00091,000371,208Dec 19 04:09 PM
Sze RandollChief Financial OfficerDec 17Buy13.251,00013,2504,000Dec 17 04:11 PM
WU JINNDirectorDec 16Option Exercise4.5530,000136,500351,208Dec 18 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 16Option Exercise4.5515,00068,2503,095,959Dec 17 04:08 PM
Fok MansonDirectorNov 07Buy11.6750,000583,5001,869,609Nov 12 04:06 PM
MGNX MacroGenics, Inc. daily Stock Chart
MGNX [NASD]
MacroGenics, Inc.
Index- P/E- EPS (ttm)-3.38 Insider Own0.20% Shs Outstand50.02M Perf Week-9.50%
Market Cap1.23B Forward P/E- EPS next Y-2.26 Insider Trans-51.06% Shs Float43.94M Perf Month-10.53%
Income-166.60M PEG- EPS next Q-0.93 Inst Own98.50% Short Float9.10% Perf Quarter-16.07%
Sales77.90M P/S15.76 EPS this Y24.60% Inst Trans2.36% Short Ratio8.06 Perf Half Y191.04%
Book/sh4.95 P/B4.46 EPS next Y37.90% ROA-53.00% Target Price29.40 Perf Year145.44%
Cash/sh4.19 P/C5.27 EPS next 5Y- ROE-72.10% 52W Range4.04 - 32.18 Perf YTD103.03%
Dividend- P/FCF- EPS past 5Y-17.70% ROI-76.80% 52W High-31.35% Beta2.39
Dividend %- Quick Ratio5.70 Sales past 5Y6.10% Gross Margin- 52W Low446.78% ATR1.40
Employees384 Current Ratio5.70 Sales Q/Q91.50% Oper. Margin- RSI (14)33.53 Volatility5.68% 4.98%
OptionableYes Debt/Eq0.00 EPS Q/Q-44.10% Profit Margin- Rel Volume0.59 Prev Close22.68
ShortableYes LT Debt/Eq0.00 EarningsJul 30 AMC Payout- Avg Volume495.95K Price22.09
Recom2.00 SMA20-11.06% SMA50-15.84% SMA20017.91% Volume292,882 Change-2.60%
Aug-03-20Downgrade Citigroup Buy → Neutral $25 → $26
Jun-01-20Upgrade Guggenheim Neutral → Buy
May-26-20Reiterated H.C. Wainwright Buy $22 → $40
Mar-04-20Initiated Barclays Underweight $8
Dec-19-19Initiated Cantor Fitzgerald Overweight
Dec-18-19Initiated Cantor Fitzgerald Overweight
Nov-21-19Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $6
Nov-20-19Resumed Guggenheim Neutral
May-03-19Upgrade Wedbush Neutral → Outperform $26
Apr-12-19Initiated Guggenheim Neutral
Feb-07-19Upgrade Citigroup Sell → Buy
Feb-07-19Downgrade Wedbush Outperform → Neutral
Feb-06-19Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19Downgrade Citigroup Neutral → Sell $10
Dec-10-18Downgrade Raymond James Outperform → Underperform
Sep-10-18Resumed BTIG Research Buy $30
May-31-18Initiated Evercore ISI Outperform $33
Mar-05-18Initiated H.C. Wainwright Buy $38
Mar-31-17Initiated Raymond James Outperform $26
Mar-02-17Initiated Instinet Buy $41
Oct-15-20 04:30PM  
Oct-05-20 11:19AM  
Sep-23-20 07:15AM  
Sep-22-20 04:30PM  
Sep-21-20 07:30AM  
Sep-20-20 09:10AM  
Sep-16-20 10:37AM  
Sep-03-20 07:30AM  
Aug-05-20 04:30PM  
Aug-02-20 10:21AM  
Aug-01-20 03:03AM  
Jul-31-20 06:55AM  
Jul-30-20 06:40PM  
04:01PM  
Jul-23-20 07:30AM  
Jul-22-20 12:32PM  
Jul-09-20 06:43PM  
05:22PM  
Jun-27-20 09:28PM  
Jun-22-20 09:00AM  
Jun-16-20 07:30AM  
Jun-05-20 07:30AM  
Jun-03-20 04:05PM  
May-29-20 12:45PM  
May-28-20 07:30AM  
May-27-20 07:30AM  
03:50AM  
May-21-20 04:05PM  
May-18-20 07:06AM  
May-13-20 05:10PM  
May-12-20 08:40AM  
May-11-20 04:37PM  
11:14AM  
06:29AM  
May-08-20 08:10AM  
07:34AM  
May-06-20 03:01PM  
01:24PM  
May-05-20 06:45PM  
04:01PM  
08:36AM  
Apr-29-20 04:01PM  
Apr-28-20 04:01PM  
07:30AM  
Apr-27-20 12:05AM  
Apr-20-20 09:01AM  
Apr-17-20 08:54AM  
Mar-16-20 06:16PM  
Mar-10-20 01:50AM  
Mar-04-20 05:00PM  
Mar-02-20 08:45AM  
Feb-27-20 10:30AM  
07:30AM  
Feb-25-20 04:01PM  
Feb-24-20 02:48PM  
Feb-13-20 07:30AM  
Feb-10-20 07:30AM  
Jan-14-20 03:12PM  
Jan-13-20 07:30AM  
Jan-09-20 04:30PM  
Jan-06-20 05:14PM  
Dec-19-19 12:00PM  
Dec-11-19 10:00AM  
Dec-09-19 03:05PM  
Dec-07-19 08:35AM  
Nov-15-19 12:02PM  
Nov-13-19 04:55PM  
Nov-12-19 01:45PM  
12:45PM  
10:59AM  
10:29AM  
10:00AM  
09:36AM  
07:37AM  
03:29AM  
02:00AM  
Nov-11-19 03:35PM  
03:21PM  
01:45PM  
12:15PM  
12:00PM  
10:40AM  
09:41AM  
07:10AM  
Nov-10-19 12:00PM  
10:30AM  
Nov-09-19 07:35PM  
11:52AM  
Nov-08-19 08:15PM  
04:59PM  
03:00PM  
02:15PM  
01:00PM  
11:20AM  
10:40AM  
10:23AM  
09:50AM  
Nov-07-19 08:05PM  
05:30PM  
04:45PM  
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Risser Eric BlasiusSr VP & Chief Business OfficerSep 28Option Exercise1.5150075544,968Sep 29 04:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerSep 28Sale25.3350012,66544,468Sep 29 04:44 PM
Bonvini EzioSr VP, Research & CSOSep 18Sale32.0018,339586,84883,807Sep 21 04:51 PM
Bonvini EzioSr VP, Research & CSOSep 17Sale29.8844,5121,330,019102,146Sep 21 04:51 PM
Galbraith KennethDirectorSep 09Option Exercise17.3820,773361,10313,849Sep 10 04:44 PM
Galbraith KennethDirectorSep 09Sale27.1120,773563,1560Sep 10 04:44 PM
Spitznagel ThomasSr VP, BPD & ManufacturingAug 20Option Exercise7.517,50056,3257,500Aug 21 04:05 PM
Spitznagel ThomasSr VP, BPD & ManufacturingAug 20Sale26.877,500201,5250Aug 21 04:05 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 27Option Exercise1.454,4896,50048,468Jul 28 05:12 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 27Sale25.474,489114,31944,468Jul 28 05:12 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 02Option Exercise1.513,1004,68147,568Jul 06 04:25 PM
Peters Jeffrey StuartGeneral CounselJul 02Sale30.002026,0600Jul 06 04:25 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 02Sale30.003,10093,00044,468Jul 06 04:25 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJun 24Option Exercise0.9450047044,968Jun 25 04:57 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJun 24Sale28.4950014,24544,468Jun 25 04:57 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 26Option Exercise0.9450047044,968May 27 04:43 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 26Sale26.5950013,29544,468May 27 04:43 PM
Spitznagel ThomasSr VP, BPD & ManufacturingMay 20Option Exercise7.517,50056,3257,500May 21 07:44 PM
Spitznagel ThomasSr VP, BPD & ManufacturingMay 20Sale25.307,500189,7500May 21 07:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 06Option Exercise1.478,03211,84352,500May 07 04:22 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 06Sale20.958,032168,30044,468May 07 04:22 PM
Risser Eric BlasiusSr VP & Chief Business OfficerApr 16Option Exercise0.946,0005,64044,468Apr 17 04:11 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMar 13Option Exercise0.946,0005,64038,468Mar 17 04:09 PM
Koenig ScottPresident and CEOMar 11Option Exercise0.94133,163125,173943,103Mar 13 04:15 PM
Karrels JamesSVP, CFO and SecretaryMar 06Option Exercise0.944,4734,205152,460Mar 09 04:39 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 20Option Exercise0.9450047032,968Feb 21 04:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 20Sale10.845005,42032,468Feb 21 04:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 05Option Exercise0.9462358633,091Feb 06 04:41 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 05Sale10.006236,23032,468Feb 06 04:41 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 04Option Exercise0.94302832,498Feb 06 04:41 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 04Sale10.003030032,468Feb 06 04:41 PM
Karrels JamesSVP, CFO and SecretaryJan 30Option Exercise0.9412,50011,750147,987Jan 31 04:45 PM
ETNB 89bio, Inc. daily Stock Chart
ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-4.57 Insider Own- Shs Outstand13.80M Perf Week2.95%
Market Cap486.16M Forward P/E- EPS next Y-3.92 Insider Trans- Shs Float6.44M Perf Month0.04%
Income-60.30M PEG- EPS next Q-0.84 Inst Own69.70% Short Float7.74% Perf Quarter-22.47%
Sales- P/S- EPS this Y-210.60% Inst Trans-3.03% Short Ratio3.14 Perf Half Y-10.12%
Book/sh5.06 P/B4.83 EPS next Y-27.80% ROA-86.70% Target Price- Perf Year-
Cash/sh3.71 P/C6.58 EPS next 5Y16.00% ROE-130.00% 52W Range14.00 - 47.25 Perf YTD-7.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.30% Beta-
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low74.50% ATR1.62
Employees24 Current Ratio11.10 Sales Q/Q- Oper. Margin- RSI (14)40.35 Volatility5.80% 5.50%
OptionableNo Debt/Eq0.00 EPS Q/Q47.00% Profit Margin- Rel Volume0.48 Prev Close24.46
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume158.77K Price24.43
Recom1.40 SMA20-0.43% SMA50-17.66% SMA200-13.24% Volume76,042 Change-0.12%
Oct-19-20Initiated Raymond James Strong Buy $65
Sep-25-20Upgrade BofA Securities Neutral → Buy $37 → $43
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
Sep-28-20 05:18PM  
Sep-23-20 07:00AM  
Sep-16-20 08:51PM  
Sep-14-20 05:21PM  
07:01AM  
Sep-13-20 07:53PM  
Sep-03-20 08:30AM  
Aug-13-20 04:05PM  
Aug-11-20 08:32AM  
Aug-10-20 12:15PM  
12:09PM  
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLCDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:09 PM
Naschitz AnatDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17Buy28.001,300,00036,400,0004,736,214Sep 21 04:30 PM
Longitude Capital Partners III10% OwnerJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:11 PM
Grunberg GregoryDirectorJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:08 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 08Buy27.50275,0007,562,5003,436,214Jul 10 04:32 PM
BPMC Blueprint Medicines Corporation daily Stock Chart
BPMC [NASD]
Blueprint Medicines Corporation
Index- P/E- EPS (ttm)-7.66 Insider Own1.10% Shs Outstand54.22M Perf Week2.29%
Market Cap5.68B Forward P/E- EPS next Y-7.32 Insider Trans-23.36% Shs Float53.91M Perf Month18.62%
Income-395.00M PEG- EPS next Q7.72 Inst Own97.90% Short Float7.81% Perf Quarter38.16%
Sales75.20M P/S75.58 EPS this Y-34.80% Inst Trans-0.18% Short Ratio9.93 Perf Half Y47.63%
Book/sh10.72 P/B9.76 EPS next Y-537.70% ROA-49.70% Target Price102.57 Perf Year36.02%
Cash/sh9.61 P/C10.89 EPS next 5Y22.27% ROE-70.40% 52W Range43.29 - 105.50 Perf YTD30.66%
Dividend- P/FCF- EPS past 5Y-32.50% ROI-77.80% 52W High-0.79% Beta0.98
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin99.80% 52W Low141.79% ATR3.51
Employees419 Current Ratio5.40 Sales Q/Q62.70% Oper. Margin- RSI (14)71.26 Volatility3.52% 3.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-11.60% Profit Margin- Rel Volume0.73 Prev Close102.82
ShortableYes LT Debt/Eq0.00 EarningsOct 29 BMO Payout- Avg Volume423.82K Price104.67
Recom1.70 SMA207.32% SMA5023.94% SMA20045.74% Volume308,497 Change1.80%
Jul-15-20Reiterated H.C. Wainwright Buy $66 → $110
May-05-20Initiated Barclays Equal Weight $59
Mar-17-20Upgrade BMO Capital Markets Market Perform → Outperform $74 → $89
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Nov-06-19Upgrade Raymond James Outperform → Strong Buy $106 → $112
Oct-22-19Initiated JMP Securities Mkt Outperform $106
Oct-03-19Initiated H.C. Wainwright Buy $100
Sep-12-19Upgrade Raymond James Mkt Perform → Outperform
Aug-29-19Initiated Piper Jaffray Neutral $85
Aug-15-19Resumed Raymond James Mkt Perform
Jul-18-19Initiated Deutsche Bank Buy $110
May-23-19Resumed Goldman Buy $125
Apr-03-19Initiated Morgan Stanley Overweight $112
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Sep-29-17Initiated BTIG Research Buy $90
Apr-05-17Reiterated Wedbush Outperform $43 → $50
Mar-13-17Upgrade Goldman Neutral → Buy
Feb-15-17Initiated Morgan Stanley Overweight
Oct-22-20 08:00AM  
Oct-02-20 04:01PM  
Sep-30-20 07:17AM  
Sep-29-20 11:46AM  
Sep-28-20 12:38PM  
Sep-25-20 11:46AM  
Sep-23-20 12:54PM  
09:30AM  
08:05AM  
Sep-22-20 04:23PM  
07:00AM  
Sep-20-20 08:25AM  
Sep-17-20 08:00AM  
Sep-13-20 07:27AM  
Sep-09-20 08:29PM  
04:01PM  
Sep-04-20 07:00PM  
08:00AM  
Sep-01-20 08:00AM  
Aug-29-20 11:31AM  
Aug-04-20 08:00AM  
Aug-01-20 08:21AM  
Jul-31-20 11:18AM  
Jul-30-20 08:35AM  
07:28AM  
07:00AM  
Jul-24-20 08:30AM  
Jul-23-20 08:00AM  
Jul-14-20 05:22PM  
12:23PM  
12:22PM  
08:28AM  
08:04AM  
06:23AM  
03:56AM  
01:00AM  
Jul-13-20 08:25PM  
Jul-02-20 04:01PM  
12:25PM  
Jul-01-20 08:00AM  
Jun-29-20 06:30PM  
Jun-06-20 09:00AM  
Jun-05-20 11:32AM  
Jun-03-20 08:00AM  
07:11AM  
03:05AM  
May-29-20 01:13PM  
08:00AM  
May-27-20 04:30PM  
May-26-20 08:00AM  
May-18-20 12:16PM  
May-15-20 12:10PM  
08:00AM  
May-14-20 11:29PM  
12:00PM  
09:00AM  
May-12-20 11:36AM  
May-07-20 12:58PM  
08:01AM  
May-06-20 08:35AM  
07:00AM  
Apr-28-20 11:19AM  
10:27AM  
07:00AM  
Apr-16-20 06:30AM  
Apr-09-20 12:00PM  
Apr-01-20 08:00AM  
Mar-27-20 03:51PM  
Mar-16-20 07:00AM  
Mar-14-20 11:30AM  
Mar-09-20 09:00AM  
Mar-06-20 06:10AM  
Feb-20-20 03:45AM  
Feb-19-20 06:16PM  
08:00AM  
Feb-18-20 12:52PM  
Feb-14-20 10:42AM  
Feb-13-20 10:31AM  
08:25AM  
Feb-07-20 11:21AM  
07:32AM  
Feb-06-20 08:00AM  
Feb-03-20 11:27AM  
Jan-30-20 11:04AM  
Jan-22-20 10:24PM  
08:25AM  
Jan-21-20 04:01PM  
Jan-16-20 04:59AM  
Jan-13-20 08:00AM  
Jan-12-20 12:19PM  
Jan-11-20 06:45PM  
Jan-10-20 10:27AM  
08:49AM  
Jan-09-20 05:16PM  
03:52PM  
10:31AM  
Jan-08-20 08:00AM  
Jan-07-20 10:26AM  
Jan-06-20 08:00AM  
Dec-13-19 09:25AM  
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Goldberg Mark AlanDirectorOct 19Option Exercise19.535,455106,5369,017Oct 21 04:21 PM
Goldberg Mark AlanDirectorOct 19Sale105.005,455572,7753,562Oct 21 04:21 PM
Haviland KateChief Operating OfficerOct 16Option Exercise36.0513,334480,69156,172Oct 20 04:09 PM
Haviland KateChief Operating OfficerOct 16Sale101.2313,3341,349,84842,838Oct 20 04:09 PM
Goldberg Mark AlanDirectorOct 07Option Exercise19.535,454106,5179,016Oct 09 04:04 PM
Albers Jeffrey W.CEO and PresidentOct 07Option Exercise8.805,00044,000146,434Oct 09 04:05 PM
Hurley ArielPrincipal Accounting OfficerOct 07Option Exercise8.806005,28010,584Oct 09 04:06 PM
Albers Jeffrey W.CEO and PresidentOct 07Sale99.175,000495,850141,434Oct 09 04:05 PM
Goldberg Mark AlanDirectorOct 07Sale100.005,454545,4003,562Oct 09 04:04 PM
Hurley ArielPrincipal Accounting